Results of analysis of gene expression data from female non-smoking lung cancer patients identified NR4A1 as a potential target gene and they demonstrated that nilotinib, a protein-tyrosine kinase inhibitor, was also an NR4A1 ligand that inhibited lung cancer cell growth (Sun et al., 2019). Here, NR4A1 is linked to lung cancer.